Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1

Conditions

Constipation 6Intestinal Diseases 5Pain 3Neoplasms 3Urinary Bladder Neoplasms 2Peritoneal Neoplasms 1Ovarian Neoplasms 1Opioid-Induced Constipation 1Ileus 1Fallopian Tube Neoplasms 1Cancer Pain 1

Interventions

Morphine 16Oxycodone 14Fentanyl 10Methadone 7nabiximols 5Lidocaine 5Acetaminophen 5resiniferatoxin 4Hydromorphone 4Ethanol 4Acupuncture Therapy 4Transcutaneous Electric Nerve Stimulation 3Buprenorphine 3Transcranial Direct Current Stimulation 2Tapentadol 2Surveys and Questionnaires 2Standard of Care 2Sodium Bicarbonate 2Radiosurgery 2Radiofrequency Ablation 2Pharmaceutical Services 2Naloxone 2Ketamine 2Electroacupuncture 2Dronabinol 2Control Groups 2Analgesics, Opioid 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2tanezumab 1rofecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cancer Pain × alvimopan × Clear all
NCT00101998 2017-08-30

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
233 enrolled
Other

Cancer Pain, Constipation, Intestinal Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡